STOCK TITAN
  1. Home
  2. News
  3. ICAD

Icad Inc - $ICAD STOCK NEWS

Welcome to our dedicated page for Icad news (Ticker: $ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icad's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icad's position in the market.

News
UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
Rhea-AI Summary

iCAD, Inc. (NASDAQ: ICAD) will report its financial results for the first quarter of 2024 on May 15, 2024, and host a conference call at 8:30 AM Eastern Time. The company specializes in AI-powered cancer detection solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
Rhea-AI Summary

iCAD, Inc. will report its first quarter financial results on May 15, 2024. The company specializes in AI-powered cancer detection solutions. The earnings call will provide insights into the company's performance for the quarter ended March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences earnings
-
News
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
Rhea-AI Summary
iCAD, Inc. announces partnership with Densitas and showcases ProFound Cloud at SBI symposium, highlighting advancements in breast cancer detection technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
partnership
News
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
Rhea-AI Summary
iCAD partners with Densitas to offer a comprehensive breast health solution, integrating AI-powered solutions for breast cancer screening, detection, density assessment, and risk evaluation. The collaboration aims to enhance early cancer detection and intervention, providing a holistic approach to precision breast health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
partnership AI
-
News
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Rhea-AI Summary
iCAD's AI Algorithm Successfully Detects Breast Arterial Calcification, Signaling Cardiovascular Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
AI
-
News
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
Rhea-AI Summary
iCAD partners with RAD-AID International to implement ProFound AI Detection for improving mammography reading and breast cancer detection in low-resource institutions and medically underserved communities. The collaboration aims to enhance breast imaging accuracy and efficiency in Guyana and other LMICs, promoting early cancer detection and health equity globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
partnership AI
News
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale
Rhea-AI Summary
iCAD, Inc. announces the commercial availability of ProFound Cloud, a Software-as-a-Service platform powered by Google Cloud and AI innovations, revolutionizing breast cancer detection. The platform provides cost-effective, secure, and scalable access to AI solutions for medical providers, enhancing patient outcomes through early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
AI
-
News
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) introduces advanced features in its ProFound Detection solution for mammography, enhancing radiologists' interpretability and efficiency. The new capabilities include limiting lesion marks, color-coding lesions, and providing color-coded ProFound Scorecards. These features aim to streamline the diagnostic process, improve readability, and aid in accurate cancer detection, showcasing iCAD's commitment to advancing cancer detection technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
News
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) reports annual recurring revenue of $8.7 million, a 15% increase year-over-year. Full-year operating cash flow improved to ($5) million from ($12.8) million. Despite a 13% decrease in total revenues for 2023, the company saw a rise in gross profit margin to 91% in Q4 2023. The GAAP net loss from continuing operations improved to ($0.5) million in Q4 2023. iCAD's President and CEO, Dana Brown, highlighted strong execution and progress towards the company's transformation plan. iCAD remains optimistic about its cash resources and future operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
earnings
News
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Rhea-AI Summary
iCAD, Inc. highlights clinical evidence showing its AI solutions can reduce breast interval cancer rates and recall rates while lowering radiology reading workload. The company's ProFound Detection solution may serve as a biomarker for evaluating cardiovascular disease. New research presented at ECR 2024 demonstrates the efficacy of iCAD's AI in improving mammography screening efficiency and accuracy. The company also introduces enhancements to its ProFound Detection solution and showcases its Breast Health Suite at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
clinical trial
Stock ICAD logo
Icad Inc

Nasdaq:ICAD

ICAD Rankings

#4913 Ranked by Market Cap
#3880 Ranked by Stock Gains
N/A Ranked by Dividends

ICAD Stock Data

37.18M
24.81M
5.82%
28.53%
1.71%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
NASHUA

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.